Pentwater Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Pentwater Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,250,000	Closed	-$211M	–	93
2026 Q1	$211M	Buy	+5,250,000	New	+$113M	1.1%	21

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Pentwater Capital Management's APLS Position: Q2 2026 in Review

Pentwater Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,250,000 shares — an estimated $211M sold.

Pentwater Capital Management first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $211M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Pentwater Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Pentwater Capital Management sold 5,250,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $211M.
Pentwater Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Pentwater Capital Management's Apellis Pharmaceuticals position peaked at $211M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Pentwater Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.